L19TNF
L19TNF is a pharmaceutical drug with 7 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
4
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Clinical Trials (7)
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7